High-dose daptomycin in documented Staphylococcus aureus infections

Matteo Bassetti, Elena Nicco, Francesca Ginocchio, Filippo Ansaldi, Daniela de Florentiis, Claudio Viscoli

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Daptomycin is approved at a dose of 4-6. mg/kg/day for the treatment of complicated skin and soft-tissue infection and Staphylococcus aureus bloodstream infection. Clinical experience with doses >6. mg/kg/day is limited, but data reported to date suggest that daptomycin can be safe and effective at higher doses. We describe our experience with daptomycin at doses >6. mg/kg/day and ≤6. mg/kg/day for S. aureus infections. A retrospective chart review of all patients treated with daptomycin from January 2008 to 28 February 2010 was performed. During the study period, 53 patients received daptomycin, including 22 patients receiving daptomycin at a standard dose (SD) (mean 5. mg/kg/day, range 4-6. mg/kg/day) and 31 patients receiving a higher dose (HD) (mean 8. mg/kg/day, range 7-9. mg/kg). The median treatment duration was 13.5 days and 19 days for the SD and HD groups, respectively. Clinical success was observed in 16/22 patients (73%) in the SD group and 29/31 patients (94%) in the HD group (P= 0.05). Microbiological success was observed in 13/19 patients (68%) and 27/29 patients (93%) in the SD and HD groups, respectively (P<0.05). Of the 53 patients, 2/22 treated with SD daptomycin and 3/31 treated with HD daptomycin experienced a grade 1 adverse event while receiving therapy (i.e. anaemia, diarrhoea, nausea, hypokalaemia and arthralgia) but did not require discontinuation of daptomycin treatment. These results suggest that daptomycin may be used at doses higher than 6. mg/kg/day without toxicity and possibly with better outcome than conventional doses. We recommend further randomised controlled prospective studies with higher doses of daptomycin.

Original languageEnglish
Pages (from-to)459-461
Number of pages3
JournalInternational Journal of Antimicrobial Agents
Volume36
Issue number5
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Daptomycin
Staphylococcus aureus
Infection
Soft Tissue Infections
Hypokalemia
Arthralgia
Therapeutics
Nausea
Anemia
Diarrhea

Keywords

  • Bacteraemia
  • CPK
  • Daptomycin
  • High dose
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

High-dose daptomycin in documented Staphylococcus aureus infections. / Bassetti, Matteo; Nicco, Elena; Ginocchio, Francesca; Ansaldi, Filippo; de Florentiis, Daniela; Viscoli, Claudio.

In: International Journal of Antimicrobial Agents, Vol. 36, No. 5, 11.2010, p. 459-461.

Research output: Contribution to journalArticle

Bassetti, Matteo ; Nicco, Elena ; Ginocchio, Francesca ; Ansaldi, Filippo ; de Florentiis, Daniela ; Viscoli, Claudio. / High-dose daptomycin in documented Staphylococcus aureus infections. In: International Journal of Antimicrobial Agents. 2010 ; Vol. 36, No. 5. pp. 459-461.
@article{9d7cd85f8a5b46b187ec25e4e927972d,
title = "High-dose daptomycin in documented Staphylococcus aureus infections",
abstract = "Daptomycin is approved at a dose of 4-6. mg/kg/day for the treatment of complicated skin and soft-tissue infection and Staphylococcus aureus bloodstream infection. Clinical experience with doses >6. mg/kg/day is limited, but data reported to date suggest that daptomycin can be safe and effective at higher doses. We describe our experience with daptomycin at doses >6. mg/kg/day and ≤6. mg/kg/day for S. aureus infections. A retrospective chart review of all patients treated with daptomycin from January 2008 to 28 February 2010 was performed. During the study period, 53 patients received daptomycin, including 22 patients receiving daptomycin at a standard dose (SD) (mean 5. mg/kg/day, range 4-6. mg/kg/day) and 31 patients receiving a higher dose (HD) (mean 8. mg/kg/day, range 7-9. mg/kg). The median treatment duration was 13.5 days and 19 days for the SD and HD groups, respectively. Clinical success was observed in 16/22 patients (73{\%}) in the SD group and 29/31 patients (94{\%}) in the HD group (P= 0.05). Microbiological success was observed in 13/19 patients (68{\%}) and 27/29 patients (93{\%}) in the SD and HD groups, respectively (P<0.05). Of the 53 patients, 2/22 treated with SD daptomycin and 3/31 treated with HD daptomycin experienced a grade 1 adverse event while receiving therapy (i.e. anaemia, diarrhoea, nausea, hypokalaemia and arthralgia) but did not require discontinuation of daptomycin treatment. These results suggest that daptomycin may be used at doses higher than 6. mg/kg/day without toxicity and possibly with better outcome than conventional doses. We recommend further randomised controlled prospective studies with higher doses of daptomycin.",
keywords = "Bacteraemia, CPK, Daptomycin, High dose, Staphylococcus aureus",
author = "Matteo Bassetti and Elena Nicco and Francesca Ginocchio and Filippo Ansaldi and {de Florentiis}, Daniela and Claudio Viscoli",
year = "2010",
month = "11",
doi = "10.1016/j.ijantimicag.2010.07.011",
language = "English",
volume = "36",
pages = "459--461",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - High-dose daptomycin in documented Staphylococcus aureus infections

AU - Bassetti, Matteo

AU - Nicco, Elena

AU - Ginocchio, Francesca

AU - Ansaldi, Filippo

AU - de Florentiis, Daniela

AU - Viscoli, Claudio

PY - 2010/11

Y1 - 2010/11

N2 - Daptomycin is approved at a dose of 4-6. mg/kg/day for the treatment of complicated skin and soft-tissue infection and Staphylococcus aureus bloodstream infection. Clinical experience with doses >6. mg/kg/day is limited, but data reported to date suggest that daptomycin can be safe and effective at higher doses. We describe our experience with daptomycin at doses >6. mg/kg/day and ≤6. mg/kg/day for S. aureus infections. A retrospective chart review of all patients treated with daptomycin from January 2008 to 28 February 2010 was performed. During the study period, 53 patients received daptomycin, including 22 patients receiving daptomycin at a standard dose (SD) (mean 5. mg/kg/day, range 4-6. mg/kg/day) and 31 patients receiving a higher dose (HD) (mean 8. mg/kg/day, range 7-9. mg/kg). The median treatment duration was 13.5 days and 19 days for the SD and HD groups, respectively. Clinical success was observed in 16/22 patients (73%) in the SD group and 29/31 patients (94%) in the HD group (P= 0.05). Microbiological success was observed in 13/19 patients (68%) and 27/29 patients (93%) in the SD and HD groups, respectively (P<0.05). Of the 53 patients, 2/22 treated with SD daptomycin and 3/31 treated with HD daptomycin experienced a grade 1 adverse event while receiving therapy (i.e. anaemia, diarrhoea, nausea, hypokalaemia and arthralgia) but did not require discontinuation of daptomycin treatment. These results suggest that daptomycin may be used at doses higher than 6. mg/kg/day without toxicity and possibly with better outcome than conventional doses. We recommend further randomised controlled prospective studies with higher doses of daptomycin.

AB - Daptomycin is approved at a dose of 4-6. mg/kg/day for the treatment of complicated skin and soft-tissue infection and Staphylococcus aureus bloodstream infection. Clinical experience with doses >6. mg/kg/day is limited, but data reported to date suggest that daptomycin can be safe and effective at higher doses. We describe our experience with daptomycin at doses >6. mg/kg/day and ≤6. mg/kg/day for S. aureus infections. A retrospective chart review of all patients treated with daptomycin from January 2008 to 28 February 2010 was performed. During the study period, 53 patients received daptomycin, including 22 patients receiving daptomycin at a standard dose (SD) (mean 5. mg/kg/day, range 4-6. mg/kg/day) and 31 patients receiving a higher dose (HD) (mean 8. mg/kg/day, range 7-9. mg/kg). The median treatment duration was 13.5 days and 19 days for the SD and HD groups, respectively. Clinical success was observed in 16/22 patients (73%) in the SD group and 29/31 patients (94%) in the HD group (P= 0.05). Microbiological success was observed in 13/19 patients (68%) and 27/29 patients (93%) in the SD and HD groups, respectively (P<0.05). Of the 53 patients, 2/22 treated with SD daptomycin and 3/31 treated with HD daptomycin experienced a grade 1 adverse event while receiving therapy (i.e. anaemia, diarrhoea, nausea, hypokalaemia and arthralgia) but did not require discontinuation of daptomycin treatment. These results suggest that daptomycin may be used at doses higher than 6. mg/kg/day without toxicity and possibly with better outcome than conventional doses. We recommend further randomised controlled prospective studies with higher doses of daptomycin.

KW - Bacteraemia

KW - CPK

KW - Daptomycin

KW - High dose

KW - Staphylococcus aureus

UR - http://www.scopus.com/inward/record.url?scp=77957658501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957658501&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2010.07.011

DO - 10.1016/j.ijantimicag.2010.07.011

M3 - Article

VL - 36

SP - 459

EP - 461

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 5

ER -